ArticleAntibiotics (Basel, Switzerland)2022
Temporal Variation of Meropenem Resistance in
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Characterization of antibiotic-resistant bacteria and phylogenetic analysis ofOne health (Amsterdam, Netherlands) · 2026Article
- Genotypic and phenotypic evidence of extended-spectrum β-lactamase and carbapenemase-producing shigatoxigenic and intimin-producing Escherichia coli in diarrheic calves in Bangladesh: A hidden zoonotic and public health risk.Veterinary research communications · 2026Article
- Antibacterial potential of antidepressants against extended-spectrum β-lactamase-producing Escherichia coli.Folia microbiologica · 2025Article
- Assessment of water quality and occurrence of multidrug-resistant clinically relevant bacteria in drinking water in the twin cities of Pakistan.Environmental monitoring and assessment · 2025Article
- Analyzing Antibiotic Resistance in Bacteria from Wastewater in Pakistan Using Whole-Genome Sequencing.Antibiotics (Basel, Switzerland) · 2024Article
- Occurrence, molecular characterization, and antimicrobial susceptibility of sorbitol non-fermenting Escherichia coli in lake water, fish and humans in central Oromia, Ethiopia.Scientific reports · 2024Article
- A systematic review and meta-analysis of carbapenem resistance and its possible treatment options with focus on clinicalHeliyon · 2024Article
- Antibiotic resistance genes prevalence prediction and interpretation in beaches affected by urban wastewater discharge.One health (Amsterdam, Netherlands) · 2023Article
- High prevalence of extensively drug resistant and extended spectrum beta lactamases (ESBLs) producing uropathogenic Escherichia coli isolated from Faisalabad, Pakistan.World journal of microbiology & biotechnology · 2023Article
- Artificial Intelligence for Antimicrobial Resistance Prediction: Challenges and Opportunities towards Practical Implementation.Antibiotics (Basel, Switzerland) · 2023Review
- The Distribution of Mobile Colistin-Resistant Genes, Carbapenemase-Encoding Genes, and Fluoroquinolone-Resistant Genes inAntibiotics (Basel, Switzerland) · 2022Article
- Characterization of Genomic Diversity among Carbapenem-ResistantMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO has classified carbapenem-resistant Enterobacteriaceae in most critical priority pathogens that pose a threat to human health. The present study investigated the prevalence of meropenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.